Combatting chemoresistance in GBM

Combatting chemoresistance in GBM

Posted 26 January, 2022 at 08:48

Author Jessica McClory on behalf of In Sues Name


By using a combinational therapeutic strategy, a research team have created a promising approach to combat chemoresistance in GBM.  Glioblastoma often resists front-line chemotherapies, including temozolomide, a drug that damages DNA and triggers tumour cell death. Nearly half of glioblastoma patients resist the treatment by producing a DNA-repairing enzyme, MGMT, but until recently it wasn’t clear why temozolomide wasn’t working for patients who lacked the MGMT enzyme.

Using glioblastoma cell lines and primary glioblastoma cells derived from patient tumour specimens the team discovered that inhibiting two specific proteins when combined with temozolomide, produced an effective “triple combinational therapy” that overcame chemoresistance.

The findings from this three-pronged approach to treating glioblastoma are published this week in Oncogenesis.

More from In Sues Name

New cancer treatment making headway
Press Release

New cancer treatment making headway

21 May 2022
Stronger treatments for glioblastoma
Press Release

Stronger treatments for glioblastoma

18 May 2022
Join our Golf Day this June!
Press Release

Join our Golf Day this June!

16 May 2022
More accurate diagnosis on the horizon...
Press Release

More accurate diagnosis on the horizon...

09 May 2022
Card image cap
user

In Sues Name

Charity

Profile Feed
In Sue’s Name was founded in 2014 by David Taylor in memory of his beloved daughter Sue Blasotta, who died in 2011 of brain tumours. Sue was devoted to her husband Joe and their children Sasha and Daniel. She adored her career, first in recruitment with Reed Employment and then caring for ch...

59

Press Releases